In this latest white paper, Dave Cooper, Project Pursuit Manager at Emerson, explores how forward-thinking biotech companies can meet the growing demand for personalised treatments by reimagining their manufacturing strategies.
Two-part clinical study programme to evaluate change in lean and fat mass in patients receiving two different doses of S-pindolol benzoate whilst 1) receiving the GLP-1 agonist semaglutide; and 2) after cessation of semaglutide treatment; Initial proof-of-concept data expected in second half of 2026
Brainomix and 3DR Labs announced a new strategic partnership to support acute stroke care in the US through the clinically validated and FDA-cleared Brainomix 360 Stroke.
Medicines Discovery Catapult's Chemical Protein Stability Assay generates vital data to support drug discovery innovators and will enhance Selvita’s screening platform.
The policy landscape for deep biotech has seen remarkable strides over the past year, positioning the UK as a leader in engineering biology innovation.
In 2035, we envision a UK biotech sector with a stronger long-term capital base supporting both early—and later-stage firms. To make Vision 2035 a reality, we, as a sector, must focus on areas that will have the greatest impact. Read the report to find out what those are!
Watch the recording to see how the BIA Regulatory and Access Community is driving UK life sciences forward through expert insights on ILAP, MHRA initiatives, and collaborative innovation.
Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, have entered into a research collaboration and global license agreement.
Washington’s shifting policy landscape continues to cause uncertainty, while the UK is staying calm. Join our webinar this Thursday to hear how we’re engaging with international partners and government to ensure the UK voice is heard and our sector remains robust.
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapy products for the treatment of multiple cancers, announces a partnership with the NHS Cancer Vaccine Launch Pad (CVLP) to fast-track access for NHS patients into the fourth cohort of the Company’s Phase 2 clinical SCOPE study.
Oligos explainer: A new frontier in precision medicine, highlights the transformative potential of oligonucleotide therapies. These precision medicines, which use short DNA or RNA molecules to target specific genes, offer groundbreaking solutions for diseases previously deemed untreatable, from rare genetic disorders to cancer.
Emerson partners with biopharmaceutical companies to drive innovation, efficiency, and compliance in life sciences manufacturing through cutting-edge automation and process expertise.
